A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC

Most approved vaccines against COVID-19 have to be administered in a prime/boost regimen. We engineered a novel vaccine based on a chimeric human adenovirus 5 (hAdV5) vector. The vaccine (named CoroVaxG.3) is based on three pillars: (i) high expression of Spike to enhance its immunodominance by usin...

Descripción completa

Detalles Bibliográficos
Autores principales: López, M. Verónica, Vinzón, Sabrina E., Cafferata, Eduardo G. A., Núñez, Felipe J., Soto, Ariadna, Sanchez-Lamas, Maximiliano, Afonso, M. Jimena, Aguilar-Cortes, Diana, Ríos, Gregorio D., Maricato, Juliana T., T. Braconi, Carla, B. Silveira, Vanessa, M. Andrad, Tatiane, C. S. Bonetti, Tatiana, Ramos Janini, Luiz M., Girão, Manoel J. B. C., Llera, Andrea S., Gomez, Karina A., Ortega, Hugo H., Berguer, Paula M., Podhajcer, Osvaldo L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537385/
https://www.ncbi.nlm.nih.gov/pubmed/34696219
http://dx.doi.org/10.3390/vaccines9101106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537385/
https://www.ncbi.nlm.nih.gov/pubmed/34696219
http://dx.doi.org/10.3390/vaccines9101106

Ejemplares similares